CJC-1295 (No DAC) 5mg — Vial Spec, Reconstitution Math & COA
This technical document outlines the chemical specifications, reconstitution math, and analytical testing standards for 5mg vials of CJC-1295 (No DAC). Designed for high-throughput preclinical models and multi-well biochemical assays, this single-vial specification provides researchers with precise concentration formulas, aliquot protocols, and lot-matched verification standards.
Quick answer
This technical document outlines the chemical specifications, reconstitution math, and analytical testing standards for 5mg vials of CJC-1295 (No DAC). Designed for high-throughput preclinical models and multi-well biochemical assays, this single-vial specification provides researchers with precise concentration formulas, aliquot protocols, and lot-matched verification standards.
Key takeaways
- A 5mg vial of [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC)—also designated in literature as Modified GRF 1-29—contains 5.0 milligrams of pure lyophilized peptide sequence (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2) paired with a protective mannitol or trehalose bulking agent.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC) is a 29-amino-acid synthetic peptide modified from native GHRH (1-29) by substituting four amino acids at positions 2, 8, 15, and 27.
- Accurate dilution kinetics are essential for maintaining reproducible concentration gradients in microplate assays or dosing parameters in rodent tissue repair models.
- Once a 5mg vial of [CJC-1295](/research-peptides/cjc-1295-no-dac) (No DAC) is reconstituted into liquid phase, the polypeptide structure becomes susceptible to oxidation, aggregation, and enzymatic degradation.
CJC-1295 (No DAC) 5mg Mass & Laboratory Applications
A 5mg vial of CJC-1295 (No DAC)—also designated in literature as Modified GRF 1-29—contains 5.0 milligrams of pure lyophilized peptide sequence (Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2) paired with a protective mannitol or trehalose bulking agent. This 5,000-microgram payload is specifically configured for research environments running extended protocol series, multi-subject rodent cohorts, or cell culture assays requiring standardized stock concentrations across multiple days.
In cell culture systems and animal models, CJC-1295 (No DAC) acts as a synthetic growth-hormone-releasing hormone (GHRH) analog. Researchers utilize this standard 5mg unit size to evaluate biological pathways related to pulsatile growth hormone secretion, cellular repair kinetics, and insulin-like growth factor 1 (IGF-1) expression. Laboratories select the 5mg format over smaller units when protocol designs demand larger stock volumes, reducing vial-to-vial reconstitution frequency and preserving consistency across identical research assays. To view all available packaging configurations, inspect the CJC-1295 (No DAC) product page or search our full research peptide catalog.
Molecular Structure, Receptor Affinity, and Preclinical Mechanism
CJC-1295 (No DAC) is a 29-amino-acid synthetic peptide modified from native GHRH (1-29) by substituting four amino acids at positions 2, 8, 15, and 27. These specific side-chain modifications (D-Ala2, Gln8, Ala15, Leu27) enhance enzymatic resistance against dipeptidyl peptidase-IV (DPP-IV) cleavages, extending the biological half-life from approximately 5–10 minutes (native GHRH) to roughly 30 minutes in preclinical animal models. Unlike Drug Affinity Complex (DAC) variants, the non-DAC form lacks the maleimidopropionic acid linker, preventing covalent binding to circulating serum albumin.
Preclinical studies suggest that CJC-1295 (No DAC) binds selectively to the pituitary growth hormone-releasing hormone receptor (GHRH-R), initiating a signal transduction cascade through the G-protein coupled pathway. In vitro assays demonstrate that this binding activates adenylate cyclase, raising intracellular cyclic adenosine monophosphate (cAMP) and triggering calcium influx within somatotroph cells. This pathway stimulates the synthesis and pulsatile release of endogenous growth hormone, which downstream in vitro models show drives hepatocytes and local peripheral tissues to synthesize IGF-1—a primary mediator of connective tissue repair, protein synthesis, and cellular proliferation research.
5mg Reconstitution Mathematics and Volume-Concentration Calculations
Accurate dilution kinetics are essential for maintaining reproducible concentration gradients in microplate assays or dosing parameters in rodent tissue repair models. Reconstituting a 5mg (5,000 mcg) lyophilized cake requires precise addition of sterile diluent—typically Bacteriostatic Water (0.9% benzyl alcohol) or sterile PBS—using a calibrated micropipette. Researchers can verify working concentration values with our online reconstitution calculator.
The mathematical relationship between added diluent volume ($V$) and working concentration ($C$) for a 5mg vial is governed by the standard mass formula ($C = \text{Mass} / V$): • **1.0 mL Diluent Addition:** Yields a concentration of 5.0 mg/mL (5,000 mcg/mL). Every 10 µL of solution delivers 50 mcg of active compound. This highly concentrated stock is ideal for minimal-volume micro-injections or high-density cell culture wells. • **2.0 mL Diluent Addition:** Yields a concentration of 2.5 mg/mL (2,500 mcg/mL). Every 10 µL of solution delivers 25 mcg of active sequence. This volume balances syringe measurement precision with manageable volumetric pipetting. • **3.0 mL Diluent Addition:** Yields a concentration of 1.667 mg/mL (1,666.7 mcg/mL). Every 10 µL of solution delivers 16.67 mcg of compound. This concentration is frequently selected for small animal models requiring gentle volumetric titration.
Aliquot Planning, Handling Protocols, and Solution Preservation
Once a 5mg vial of CJC-1295 (No DAC) is reconstituted into liquid phase, the polypeptide structure becomes susceptible to oxidation, aggregation, and enzymatic degradation. To maximize compound integrity throughout multi-week experimental timelines, research protocols should implement a strict aliquot workflow immediately following reconstitution.
To execute a proper aliquot strategy, gently introduce the chosen diluent down the interior glass wall of the vial to prevent shearing forces. Allow the lyophilized plug to dissolve fully without agitation or vortexing. Using sterile, low-binding microcentrifuge tubes, divide the 5mg liquid stock into working aliquots sized specifically for daily or single-assay consumption (e.g., 100 µL to 250 µL per tube). Immediately flash-freeze unused aliquots at -20°C or -80°C. This practice limits the working solution to a single freeze-thaw cycle, preserving biological activity and structural stability across extended research timelines.
Thermal Stability and Storage Guidelines for Lyophilized and Reconstituted Units
Proper thermal management ensures the peptide retains its target purity and secondary structure prior to and following fluid introduction. Unreconstituted (lyophilized) CJC-1295 (No DAC) 5mg vials maintain biochemical stability when stored under controlled environment parameters:
• **Long-Term Storage (Lyophilized):** Store at -20°C for up to 24 months. For extended research repository storage, -80°C is recommended to mitigate vacuum loss or trace moisture degradation. • **Short-Term Storage (Lyophilized):** Lyophilized vials remain stable at 2°C to 8°C (refrigerated) for up to 90 days, making them resilient during standard laboratory transit. • **Reconstituted Solution Storage:** Liquid aliquots stored at 2°C to 8°C should be utilized within 14 to 21 days when prepared with Bacteriostatic Water. Frozen aliquots (-20°C) remain stable for 3 to 6 months. Avoid repeated thermal cycling, as ice crystal formation disrupts the amide backbone of GHRH analogs.
Analytical Certificate of Analysis (COA) Verification and Quality Control
Every production lot of CJC-1295 (No DAC) 5mg manufactured for PX1 Research undergoes strict analytical verification by independent ISO 17025 accredited laboratories. We publish lot-specific documentation accessible directly through our public certificate of analysis database.
Quality assurance protocols evaluate three primary physical and chemical metrics: 1. **High-Performance Liquid Chromatography (HPLC):** Confirms chemical purity exceeds 98.0%, displaying a single major chromatographic peak and verifying the absence of truncated synthesis fragments. 2. **Mass Spectrometry (MS):** Validates precise molecular weight (3,288.1 Da theoretical mass), matching identity against synthetic standard profiles. 3. **Endotoxin Testing (LAL Assay):** Measures bacterial endotoxin levels using kinetic chromogenic methods to ensure values remain well below established research thresholds (<0.01 EU/mg), eliminating baseline inflammatory variables in cellular and animal assays.
Comparative Analysis: CJC-1295 (No DAC) vs. Related Secretagogues
In preclinical growth factor research, investigators frequently compare GHRH analogs and ghrelin receptor agonists to identify ideal secretagogue profiles for specific tissue repair or metabolic models. Below is a structural and kinetic comparison of related compounds commonly studied in conjunction with CJC-1295 (No DAC):
While CJC-1295 (No DAC) acts directly on the GHRH receptor with a ~30-minute half-life, the extended CJC-1295 with DAC variant features a drug affinity complex that binds serum albumin, extending half-life to over 6 days in preclinical models and providing continuous GHRH elevation. Conversely, growth hormone secretagogue receptor (GHSR) agonists like Ipamorelin act via a distinct, synergistic receptor pathway. When combined in dual-agonist protocols, GHRH analogs and GHSR agonists demonstrate synergistic release of growth hormone in vitro. Laboratories exploring classic GHRH structures also evaluate Sermorelin, which retains the unmodified 29-amino-acid native sequence but exhibits faster metabolic clearance than Modified GRF 1-29.
Vial Size Selection: Determining When 5mg vs. 2mg Fits Protocol Requirements
Selecting between a 2mg and a 5mg vial size depends primarily on assay throughput, subject cohort size, and project duration. If PX1 Research lists specific batch sizes on our main catalog, researchers should calculate total volume consumption to minimize waste.
The **5mg format** is optimized for high-density screening workflows, parallel longitudinal rodent studies, or laboratories running daily multi-well receptor binding assays. Using a single 5mg vial reduces batch-to-batch reconstitution variance across large testing blocks. Conversely, smaller vial sizes (such as 2mg units) are preferred for preliminary pilot studies, single-dose diagnostic assays, or short-term protocols where liquid stability limits (14–21 days) would result in leftover reconstituted product. Browse available unit options on our CJC-1295 (No DAC) product page or evaluate bulk lab options via our wholesale accounts portal.
Institutional Procurement, USA Manufacturing, and Shipping Assurance
PX1 Research supplies USA-manufactured research peptides to academic institutions, biotechnology organizations, and independent research facilities worldwide. All peptide synthesis processes take place in cGMP-compliant facilities, adhering to strict quality control standard operating procedures.
Orders are fulfilled directly from our domestic distribution centers located in California and Arizona, enabling same-day dispatch for orders placed Monday through Friday before cut-off times. Fast domestic shipping prevents extended environmental thermal exposure during transit. To review full safety documentation, explore mechanism literature in our peptide research hub, or request custom institutional order handling, contact our research support team.
Frequently Asked Questions
What is the exact chemical sequence and molecular weight of CJC-1295 (No DAC) 5mg?
CJC-1295 (No DAC), also known as Modified GRF 1-29, has the chemical sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 and a theoretical molecular weight of 3,288.1 g/mol.
How much diluent should be added to a 5mg CJC-1295 (No DAC) vial?
Diluent volume depends on your target concentration. Adding 1.0 mL of Bacteriostatic Water yields 5,000 mcg/mL (5 mcg/µL); adding 2.0 mL yields 2,500 mcg/mL (2.5 mcg/µL); and adding 3.0 mL yields 1,666.7 mcg/mL (1.67 mcg/µL).
How is lot-matched quality verified for PX1 Research 5mg vials?
Every lot undergoes independent third-party testing in an ISO 17025 accredited laboratory. Analysis includes HPLC purity verification (>98%), Mass Spectrometry identity verification, and kinetic chromogenic LAL endotoxin testing (<0.01 EU/mg). COAs are publicly accessible.
What is the primary difference between CJC-1295 No DAC and CJC-1295 with DAC?
CJC-1295 (No DAC) lacks the maleimidopropionic acid linker. Consequently, it does not bind to circulating albumin, resulting in a biological half-life of roughly 30 minutes in preclinical models (pulsatile release) compared to the >6-day half-life of the DAC variant (continuous release).
How should reconstituted 5mg CJC-1295 (No DAC) solutions be stored?
Reconstituted liquid solutions should be divided into single-use aliquots and stored at 2°C to 8°C for short-term use (up to 21 days with Bacteriostatic Water) or flash-frozen at -20°C to -80°C for long-term storage (up to 6 months). Avoid repeated freeze-thaw cycles.
Is CJC-1295 (No DAC) 5mg suitable for human or veterinary administration?
No. All products sold by PX1 Research are strictly for in vitro laboratory research, cellular assays, and preclinical animal models. They are not intended for human or veterinary use, medical treatment, diagnosis, or clinical applications.
Can CJC-1295 (No DAC) be combined with Ipamorelin in research protocols?
In preclinical research settings, GHRH analogs (like CJC-1295 No DAC) and GHSR agonists (like Ipamorelin) are frequently co-administered in vitro or in rodent models to study the dual-receptor synergistic elevation of growth hormone.
What is the shipping time for 5mg research vials from PX1 Research?
Orders ship same-day Monday through Friday when placed before cutoff times. All packages dispatch from our domestic fulfillment nodes in California and Arizona to ensure fast delivery and minimal thermal decay.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.